Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2024)
26 slides from Optiscan Imaging's shareholder meeting presentation, Nov 21, 2024
Slide 1: The new standard in digital pathology and precision surgery
The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) Annual General Meeting 21 November 2024
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 21 November 2024. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor m
Slide 3: Chairman's Address
Chairman’s Address Mr Robert Cooke Non-Executive Chairman
Slide 4: Optiscan Board: Experienced Leadership
Optiscan Board: Experienced Leadership Robert Cooke Camile Farah Sean Gardiner Karen Borg Ron Song Board Chair CEO & MD Non-Executive Director Non-Executive Director Non-Executive Director • 40-year career in • 25 years’ experience in • Managing Director • Medtech leader • Track record of health ind
Slide 5: Chairman's Address
Chairman’s Address CHAIRMAN’S AGM ADDRESS Optiscan Imaging Limited (ASX: OIL) (the ‘Company’ or ‘Optiscan’) provides the following Chairman’s address which will be made to the Annual General Meeting of shareholders 21 November 2024. At the beginning of the FY24 financial year, the Company raised $16
Slide 6: Managing Director's Report
Managing Director’s Report Dr Camile Farah CEO & Managing Director
Slide 7: Acknowledgement of Country
Acknowledgement of Country I begin today by acknowledging the Traditional Owners of the land on which we meet, the Wurundjeri and the Boon Wurrung people of the Kulin Nation, and pay my respects to their Elders past, present and emerging.
Slide 8: Optiscan at a Glance
Optiscan at a Glance A global medical technology company leading the transformation of digital pathology and precision surgery ASX: OIL Melbourne $137m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office & Plant Certification Co
Slide 9: Key Achievements - Significant Milestones FY24
Key Achievements - Significant Milestones FY24 Key Achievements FY24 $16.7m Entitlement Issue Capital Successful completion of a $16.7m capital raise to develop new clinical devices and product July 2023 innovations Product Telepathology Milestone Aug 2023 Development Project with Prolucid passes pr
Slide 10: Key Achievements - Significant Milestones FY24
Key Achievements - Significant Milestones FY24 Key Achievements FY24 Product Optiscan Reveals InVue® Device for Precision Surgery Jun 2024 Development InVue® expands Optiscan’s product portfolio into the surgical application market Capital Optiscan undertakes 2024 Investor Roadshow Jul 2024 Market C
Slide 11: Strategic Partnerships & Collaborations
Strategic Partnerships & Collaborations Robotics Veterinary Gastroenterology #1 RANKED ROBOTIC SURGERY 150 MILLION 12 MILLION GI ENDOMICROSCOPY NEXT GEN US HOSPITAL SYSTEM GLOBAL LEADERS COMPANION CATS & DOGS CANCER DIAGNOSES EARLY PIONEERS FLEXIBLE SCOPE
Slide 12: The Optiscan Opportunity
The Optiscan Opportunity Artificial Intelligence $20.9 billion Clinical Life $10 trillion Sciences $144 billion Veterinary $46.51 billion Surgery $45.4 bn $US from referenced sources.
Slide 13: Progress to date
Progress to date Artificial Intelligence o Sales & marketing appointments in AU and US o InVue® reveal (Surgery) o Outsourced business development in EU o InVivage® compliance update (Oral) o Renewed distributor agreements in APAC o Flexible scope development (GI) o ViewnVivo® expanding sales pipeli
Slide 14: Expanding Product Range - Clinical & Life Sciences
Expanding Product Range - Clinical & Life Sciences Oral Life Sciences Surgical
Slide 15: Diversified Hardware & Software Portfolio
Diversified Hardware & Software Portfolio Clinical Device Family Vision + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecular Su
Slide 16: Product Development Pipeline - Multiple Shots at Goal
Product Development Pipeline - Multiple Shots at Goal Application Stage Collaborators Veterinary IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH MONITORING Surgical CLINICAL REGULATORY IDEATION PROTOTYPING PRECLINICAL LAUNCH MONITORING 2025-2026 2027 Oral IDEATION PROTOTYP
Slide 17: Growing Footprint & Sales Pipeline
Growing Footprint & Sales Pipeline Rochester, United States Regional Office Clinical & Regulatory Affairs European Union Business Development Sales & Marketing Beijing, China Chicago, United States Distribution Business Development Sinsi Technologies Ltd Sales & Marketing Portland, United States Bus
Slide 18: FY24 Financial Highlights
FY24 Financial Highlights Strong capital position and increased income. Cash and Term Deposits $16.7m capital raised to advance multiple R&D projects $M 12 Balance sheet in FY24 remained strong with a cash and term deposit 10 balance of $11.2m 8 6 Balance as of Sep24 remains strong at $9.1m 4 2
Slide 19: FY24 Financial Highlights
FY24 Financial Highlights Advancing R&D projects, achieving strategic milestones. R&D + IP Expense $M 5 4 3 2 1 0 FY22 FY23 FY24 Increased capital allocation to R&D has yielded success Reveal of ground-breaking new microscopic medical imaging device, InVue® for precision surgery Collaboration wi
Slide 20: FY25 Market Update
FY25 Market Update Projected increased revenue from sales and other income. Revenue and Other Income FY25 Total Income (Revenue & Other Income) projected to increase up to 20%, approximately $4.2m from FY24 Revenue Other Income Revenue from sale of products $M 5 FY25 revenue from ViewnVivo® sales
Slide 21: Increasing Sales Pipeline for ViewnVivo in FY25
Increasing Sales Pipeline for ViewnVivo® in FY25 FY25 YTD - ViewnVivo® Sales Pipeline Strong Pipeline Growth: Significant progress driven by (Probability Adjusted) targeted engagements. $3,500,000 Early Success in the US: Growing interest and opportunities from key institutions. $3,000,000 Probabili
Slide 22: FY25 Market Updates
FY25 Market Updates Market Activity Optiscan has undertaken an investor roadshow and presented at multiple investor conferences over the last 6 months with increased investor and public relations engagement. Share price performance has been positive over the past year, reaching a 3-year high of
Slide 23: Positioned for Growth
Positioned for Growth Phase 1: Core foundation Phase 2: Strategic transformation Phase 3: Strategic growth o Strategic focus o Digital health solutions o Develop core platform leader and initial product o Optimised operations offering o Full suite of digital health o Investment in growth products o
Slide 24: Optiscan Investment Opportunity
Optiscan Investment Opportunity Value Proposition Revolutionary Patent- Versatility of Platform & Diversified Hardware & Limitless Growth Potential Protected Technology Global Applications Software Offerings Market Differentiators & Investment Thesis Competitive High Barrier To Entry Revenue + Marke
Slide 25: Contact Us
Contact Us Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director, Optiscan Imaging Ltd (ASX:OIL) President & CEO, Optiscan Imaging, Inc. cfarah@optiscan.com /company/Optiscan www.optiscan.com
Slide 26: References
References Clinical – Global healthcare spending - https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Finance/gx-rise-global-health-care.pdf Oral Cancer - $1.93 and CAGR of 6.5% - https://www.marketresearchfuture.com/reports/oral-cancer-treatment-market-1820 Breast Cancer - $28.8 billio
Optiscan Imaging — Shareholder Meeting (November 2024) on 6ix